Announcements
Sidley Represents BioRender in Investment Valuing Company at $900 Million
January 2, 2026
Sidley represented BioRender, a scientific communication platform with the mission of accelerating the world’s ability to learn, discover, and communicate science, in connection with a strategic investment from Dimension Capital that values the company at approximately $900 million. As part of the transaction, BioRender provided liquidity to its employees.
The Sidley team was led by Michael Podolny (Emerging Companies and Venture Capital), and included Chloe Kaufman and Celine Gruaz (Emerging Companies and Venture Capital); Nicholas Frey (Employee Benefits and Executive Compensation); and Jonathan Westreich (Tax).
Contacts
Capabilities
Suggested News & Insights
Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With SomniveraSeptember 30, 2026Sidley Represents Bluevine in Its US$340 Million Acquisition by Valley National BankSeptember 28, 2026Sidley Represents Star51 Capital in Its Investment in UltraSight’s US$24 Million FinancingSeptember 25, 2026Sidley Represents Cymphony in Its US$30 Million Series A FinancingSeptember 18, 2026When the Meeting Minutes and the AI Transcript Don’t Match: Litigation Insights From Delaware ChancerySeptember 17, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory